About this trial
Acne vulgaris is the most common skin condition affecting late adolescents worldwide.1 The prevalence of acne is said to be 85% in adults aged 12 to 25 years.2 Almost all teenagers between 15 and 17 years report having some degree of acne.3 Estimates of the lifetime occurrence of acne in the literature range from 0.1%4 to as high as 85.1%5 in the general population, depending on the age range, region, and method of sampling. Overall, acne is more common in women,8,9 but in some literature the prevalence is approximately equal in men and women.10,11
Eligibility criteria
Qualifiers
age- and sex-matched healthy volunteers, not taking any medicine, and having no personal or family history of acne.
Disqualifiers
: reluctance to take part in the study, pregnancy or lactation
intake of oral contraception or hormone therapy, history of taking any medications that affect lipid metabolism or oral isotretinoin
and systemic diseases that affect the metabolism of lipids, such as uncontrolled diabetes, hypothyroidism, nephrotic syndrome, end-stage renal failure, HIV, familial hypercholesterolemia, and metabolic syndrome.
Trial design
Treatments tested in this trial
- lipid profile